Mounjaro (tirzepatide) is covered by many insurance plans, but only for its FDA-approved use: treating type 2 diabetes. If you’re hoping to use it for weight loss without a diabetes diagnosis, coverage is far less likely, and many plans explicitly exclude it. The details depend heavily on your specific plan type, your diagnosis, and whether you’ve tried other medications first.
Coverage for Type 2 Diabetes
Most commercial insurance plans cover Mounjaro when prescribed for type 2 diabetes in adults 18 and older. Insurers generally treat this as a medically necessary medication for that diagnosis, and many will approve it for a full year at a time. Some plans have automated approval systems: if your pharmacy claims show you’ve already been taking an oral diabetes medication, the Mounjaro claim may process without any extra paperwork.
That said, “covered” doesn’t mean “no questions asked.” Even with a type 2 diabetes diagnosis, your plan will likely require one or more of the following before approving Mounjaro:
- Prior authorization: Your doctor submits documentation proving you meet the plan’s criteria, including your diagnosis and treatment history.
- Step therapy: You must have tried and failed cheaper medications first. Most plans require at least three months on metformin. Many also require that you’ve tried or have a contraindication to at least one other injectable in the same drug class, such as Ozempic, Rybelsus, or liraglutide.
- A1C or BMI thresholds: Some insurers want documentation that your blood sugar levels remain poorly controlled despite previous treatment.
If your doctor can document that you meet these requirements, approval rates for type 2 diabetes are generally favorable. The key word is “document.” Your provider’s office handles most of this, but delays are common when paperwork is incomplete.
Coverage for Weight Loss
Mounjaro is not FDA-approved for weight loss. Eli Lilly markets a separate version of the same drug, called Zepbound, specifically for chronic weight management. This distinction matters enormously for insurance purposes.
When doctors prescribe Mounjaro off-label for obesity, insurers almost always deny the claim. Many plans consider off-label weight loss use a non-covered benefit, even if the same plan covers Zepbound or Wegovy for obesity. The NAIC (the body that coordinates state insurance regulators) notes that these drugs “usually aren’t covered by insurance unless a person has a type 2 diabetes diagnosis.”
Even dedicated weight loss drugs face steep barriers. Insurers frequently require that you have an obesity-related medical condition like high cholesterol, high blood pressure, or sleep apnea before they’ll cover any weight management medication. A high BMI alone may not be enough. And many employer-sponsored plans exclude the entire anti-obesity drug category. Only about one in five large employers (those with 200+ workers) cover GLP-1 medications for weight loss at all.
Why Employers Are Pulling Back
If your insurance comes through your job, your employer has significant control over what gets covered. Self-insured employers, which include most large companies, can choose to exclude GLP-1 drugs entirely for weight loss. Many have done exactly that.
Among companies with 5,000 or more employees, 59% reported that use of these medications for weight loss was higher than they expected, and 66% said covering them had a significant impact on prescription drug spending. The result has been a wave of restrictions. Some employers pulled the entire anti-obesity drug category from their plans. Others now limit GLP-1 coverage strictly to type 2 diabetes. One employer interviewed in a KFF survey put it bluntly: “People weren’t getting off the drugs and the costs were skyrocketing.”
There’s also a growing concern among employers that some enrollees are obtaining diabetes diagnoses they don’t truly meet in order to access these medications for weight loss. Several large employers reported that GLP-1 prescriptions among their diabetic population seemed higher than the actual prevalence of diabetes in their workforce would justify.
Medicare and Medicaid
Medicare Part D covers Mounjaro for type 2 diabetes, subject to the same prior authorization and step therapy requirements as commercial plans. However, Medicare is legally prohibited from covering weight loss medications. If you’re on Medicare and want tirzepatide for obesity, the weight-loss version (Zepbound) is not an option through your Part D plan.
Medicaid is more complicated because it varies by state. Under the Medicaid Drug Rebate Program, state programs must cover nearly all FDA-approved drugs for their approved uses, which means Mounjaro for type 2 diabetes is generally covered. Weight loss drugs, however, fall into a special category that states can exclude. As of early 2026, only 13 state Medicaid programs cover GLP-1 medications for obesity treatment under their fee-for-service plans. One exception: for children, Medicaid’s early screening and treatment benefit may require coverage if a GLP-1 is deemed medically necessary.
What You’ll Pay Out of Pocket
Without any insurance or discount program, Mounjaro costs $1,112.16 per month (four pens per 28-day supply), according to Eli Lilly’s published list price. Pharmacy markups can push that number higher.
If you have commercial insurance that covers Mounjaro, your actual cost depends on your plan’s tier placement. Mounjaro often lands on a non-preferred brand tier, which means higher copays or coinsurance. You could pay anywhere from $25 to several hundred dollars per month depending on your plan’s structure.
Eli Lilly offers a savings card program that can reduce the cost to as little as $25 for a one-month or three-month supply (up to 12 pens for 84 days). This card is available to people with commercial insurance. It does not apply to government-funded plans like Medicare, Medicaid, or Tricare. Eligibility details are available at 833-807-6576 or through Lilly’s Mounjaro website.
What to Do If You’re Denied
Insurance denials for Mounjaro are common, but they’re not always the final word. Your first step is to request a written explanation of the denial, which your insurer is required to provide. This document, typically called an Explanation of Benefits, will list the specific reason for the denial and outline your appeal rights, including any deadlines.
The most effective appeals address the exact reason for denial with matching documentation. If the denial says “not medically necessary,” you need a letter from your doctor detailing your diagnosis, treatment history, and why Mounjaro is specifically needed. If the denial cites “experimental” use, your doctor should confirm the prescription is for an FDA-approved indication. If the denial is based on an “excluded procedure” or category, make sure all relevant conditions are documented, including any co-existing problems like heart disease, sleep apnea, or uncontrolled blood sugar.
Check that the correct billing and diagnosis codes were used. Coding errors are a surprisingly common cause of denials that shouldn’t have happened. Your doctor’s office typically handles the initial appeal, but you can submit one yourself if they don’t. If you exhaust your plan’s internal appeals, most states allow you to request an external review by an independent third party.
For people on self-insured employer plans, the process works similarly, but your employer’s benefits or HR department may need to provide the formal denial letter if the insurance company won’t. Pay close attention to time limits at each stage. Missing a deadline can forfeit your right to appeal.